Patents Assigned to Aurinia Pharmaceuticals Inc.
-
Publication number: 20240077469Abstract: Provided herein are methods of employing pharmacodynamics regimens to maximize effectiveness of voclosporin in treatment of proteinuric kidney diseases while minimizing undesirable side effects, such as but not limited to calcineurin inhibitor nephrotoxicity. Also provided are methods of assessments of renal functions and/or conditions, and corresponding protocols to modify, stop, restore and/or re-initiate voclosporin dosing and administrations to maximize effectiveness of voclosporin in treatment of proteinuric kidney diseases while minimizing undesirable side effects.Type: ApplicationFiled: January 14, 2022Publication date: March 7, 2024Applicant: Aurinia Pharmaceuticals Inc.Inventors: Michael MARTIN, Robert B. HUIZINGA, Neil SOLOMONS
-
Publication number: 20230381271Abstract: Provided herein are methods of employing pharmacodynamics regimens to maximize effectiveness of voclosporin in treatment of proteinuric kidney diseases while minimizing undesirable side effects, such as but not limited to calcineurin inhibitor nephrotoxicity. Also provided are methods of assessments of renal functions and/or conditions, and corresponding protocols to modify, stop, restore and/or re-initiate voclosporin dosing and administrations to maximize effectiveness of voclosporin in treatment of proteinuric kidney diseases while minimizing undesirable side effects.Type: ApplicationFiled: July 28, 2023Publication date: November 30, 2023Applicant: Aurinia Pharmaceuticals Inc.Inventors: Michael Martin, Robert B. Huizinga, Neil Solomons
-
Publication number: 20230183293Abstract: Provided herein are methods of using voclosporin for treating or preventing coronavirus infection, particularly in subjects that require immunosuppression.Type: ApplicationFiled: May 8, 2021Publication date: June 15, 2023Applicant: Aurinia Pharmaceuticals Inc.Inventors: Y.K. Onno TENG, Robert B. HUIZINGA, Neil SOLOMONS, Jennifer CROSS
-
Patent number: 11622991Abstract: By employing a pharmacodynamic dosing regimen, the effectiveness of a protocol for treatment of a proteinuric kidney disease with voclosporin can be maximized while minimizing undesirable side effects.Type: GrantFiled: April 4, 2022Date of Patent: April 11, 2023Assignee: Aurinia Pharmaceuticals Inc.Inventors: Neil Solomons, Robert B. Huizinga
-
Publication number: 20220226428Abstract: By employing a pharmacodynamic dosing regimen, the effectiveness of a protocol for treatment of a proteinuric kidney disease with voclosporin can be maximized while minimizing undesirable side effects.Type: ApplicationFiled: April 4, 2022Publication date: July 21, 2022Applicant: Aurinia Pharmaceuticals Inc.Inventors: Neil SOLOMONS, Robert B. HUIZINGA
-
Publication number: 20210338769Abstract: The embodiments disclosed herein relate to ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly to methods for treating an ocular disease and/or condition using the disclosed compositions. According to aspects illustrated herein, there is provided a pharmaceutical composition that includes a calcineurin inhibitor or an mTOR inhibitor; a first surfactant with an HLB index greater than about 10; and a second surfactant with an HLB index of greater than about 13, wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3, and wherein the composition forms mixed micelles.Type: ApplicationFiled: April 12, 2021Publication date: November 4, 2021Applicant: Aurinia Pharmaceuticals Inc.Inventors: Ashim K. MITRA, Poonam R. VELAGALETI, Subramanian NATESAN
-
Patent number: 10973871Abstract: The embodiments disclosed herein relate to ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly to methods for treating an ocular disease and/or condition using the disclosed compositions. According to aspects illustrated herein, there is provided a pharmaceutical composition that includes a calcineurin inhibitor or an mTOR inhibitor; a first surfactant with an HLB index greater than about 10; and a second surfactant with an HLB index of greater than about 13, wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3, and wherein the composition forms mixed micelles.Type: GrantFiled: February 8, 2019Date of Patent: April 13, 2021Assignee: AURINIA PHARMACEUTICALS, INC.Inventors: Ashim K. Mitra, Poonam R. Velagaleti, Subramanian Natesan
-
Patent number: 10472394Abstract: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. Mixtures of ISATX247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity.Type: GrantFiled: August 14, 2017Date of Patent: November 12, 2019Assignee: AURINIA PHARMACEUTICALS INC.Inventors: Selvaraj A. Naicker, Randall W Yatscoff, Robert T Foster
-
Publication number: 20190224275Abstract: By employing a pharmacodynamic dosing regimen, the effectiveness of a protocol for treatment of a proteinuric kidney disease with voclosporin can be maximized while minimizing undesirable side effects.Type: ApplicationFiled: April 3, 2019Publication date: July 25, 2019Applicant: AURINIA PHARMACEUTICALS INC.Inventors: Neil SOLOMONS, Robert B. HUIZINGA
-
Patent number: 10286036Abstract: By employing a pharmacodynamic dosing regimen, the effectiveness of a protocol for treatment of lupus nephritis with voclosporin can be maximized while minimizing undesirable side effects.Type: GrantFiled: December 7, 2017Date of Patent: May 14, 2019Assignee: AURINIA PHARMACEUTICALS INC.Inventors: Neil Solomons, Robert B. Huizinga
-
Patent number: 10265375Abstract: The embodiments disclosed herein relate to ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly to methods for treating an ocular disease and/or condition using the disclosed compositions. According to aspects illustrated herein, there is provided a pharmaceutical composition that includes a calcineurin inhibitor or an mTOR inhibitor; a first surfactant with an HLB index greater than about 10; and a second surfactant with an HLB index of greater than about 13, wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3, and wherein the composition forms mixed micelles.Type: GrantFiled: February 20, 2015Date of Patent: April 23, 2019Assignee: Aurinia Pharmaceuticals Inc.Inventors: Ashim K. Mitra, Poonam R. Velagaleti, Subramanian Natesan
-
Publication number: 20180325995Abstract: By employing a pharmacodynamic dosing regimen, the effectiveness of a protocol for treatment of lupus nephritis with voclosporin can be maximized while minimizing undesirable side effects.Type: ApplicationFiled: December 7, 2017Publication date: November 15, 2018Applicant: AURINIA PHARMACEUTICALS INC.Inventors: Neil SOLOMONS, Robert B. HUIZINGA
-
Patent number: 9765119Abstract: The invention is directed to isomeric mixtures of cyclosporine analogs that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. Mixtures of ISATX247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. The ratio of isomers in a mixture comprises greater than about 80 percent by weight of the E-isomer and less than about 20 percent by weight of the Z-isomer, based on the total weight of the mixture.Type: GrantFiled: November 23, 2015Date of Patent: September 19, 2017Assignee: Aurinia Pharmaceuticals Inc.Inventors: Selvaraj A. Naicker, Randall W Yatscoff, Robert T Foster
-
Patent number: 9017725Abstract: Topical drug delivery systems for ophthalmic use including mixed nanomicellar formulations of water-insoluble drugs and methods of treating diseases affecting the posterior ocular segments are disclosed. In an embodiment, an aqueous ophthalmic solution includes nanomicelles in a physiologically acceptable buffer, having a pH of 5.0 to 8.0, wherein a corticosteroid at a concentration from about 0.01% w/v to about 1.00% w/v is solubilized through entrapment in a mixed micellar hydrophobic core with a corona composed of hydrophilic chains extending from the hydrophobic core, wherein the nanomicelles comprise vitamin E TPGS at a concentration ranging from about 3.0% w/v to about 5.0% w/v stabilized with octoxynol-40 at a concentration ranging from about 1.0% w/v to about 3.0% w/v.Type: GrantFiled: May 5, 2010Date of Patent: April 28, 2015Assignee: Aurinia Pharmaceuticals Inc.Inventors: Ashim K. Mitra, Poonam R. Velagaleti, Ulrich M. Grau
-
Publication number: 20140288266Abstract: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. Stereoselective pathways may utilize a Wittig reaction, or an organometallic reagent comprising inorganic elements such as boron, silicon, titanium, and lithium. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.Type: ApplicationFiled: March 18, 2014Publication date: September 25, 2014Applicant: Aurinia Pharmaceuticals, Inc.Inventors: Selvaraj A. Naicker, Randall W. Yatscoff, Robert T. Foster, Mark Abel, Seetharaman Jayaraman, Hans-Jürgen Mair, Jean-Michel Adam, Bruno Lohri
-
Publication number: 20140249092Abstract: The present disclosure relates to formulations containing cyclosporin analogs that are structurally similar to cyclosporin A, in particular isomeric mixtures of cyclosporin analogs that are structurally similar to cyclosporin A. The formulations form stable microemulsion preconcentrates and may provide superior drug bioavailability and/or may reduce one or more adverse effects associated with the administration of cyclosporin. Also disclosed are methods for using and preparing the formulations.Type: ApplicationFiled: March 9, 2014Publication date: September 4, 2014Applicant: Aurinia Pharmaceuticals, Inc.Inventors: Selvaraj A. Naicker, Randall W. Yatscoff, Robert T. Foster
-
Publication number: 20140235819Abstract: Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution of amino acid 1; and (2) deuterium substitution at key sites of metabo-lism of the cyclosporine A molecule such as amino acids 1, 4, 9. Also disclosed are methods of producing the cyclosporine derivatives and methods of producing immunosuppression with reduced toxicity using the disclosed cyclosporine derivatives.Type: ApplicationFiled: February 17, 2014Publication date: August 21, 2014Applicant: Aurinia Pharmaceuticals, Inc.Inventors: Selvaraj A. Naicker, Randall W. Yatscoff, Robert T. Foster
-
Publication number: 20140142277Abstract: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. Mixtures of ISATX247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.Type: ApplicationFiled: September 30, 2013Publication date: May 22, 2014Applicant: Aurinia Pharmaceuticals Inc.Inventors: Selvaraj A. Naicker, Randall W. Yatscoff, Robert T. Foster
-
Patent number: RE48226Abstract: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. Mixtures of ISATX247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.Type: GrantFiled: June 30, 2014Date of Patent: September 29, 2020Assignee: Aurinia Pharmaceuticals Inc.Inventors: Selvaraj A. Naicker, Randall W Yatscoff, Robert T Foster